TRACKED FOR IMPACT Indexed in: FACTOR PIMPACTubMed 6.081 FACTOR
an Open Access Journal by MDPI
Academic Open Access Publishing since 1996 TRACKED FOR IMPACT Indexed in: FACTOR PIMPACTubMed 6.0814.717 FACTOR
an Open Access Journal by MDPI
Editor-in-Chief Message from the Editor-in-Chief Prof. Dr. Shaker A. Mousa Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health Section Editors-in-Chief Dr. Vincenzo Cerullo and disease, the discovery and characterization of new Dr. Bruno Meloni therapeutic targets, therapeutic strategies, and research Prof. Dr. Jun Lu of naturally driven biomedicines, pharmaceuticals, Dr. Veronique Baud and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, biosimilar, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, biosimilars, and nano-biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.
Author Benefits Open Access Unlimited and free access for readers
Fast Manuscript Handling Time Immediate publication upon acceptance
No Copyright Constraints Retain copyright of your work and free use of your article
No Space Constraints No restriction on the length of the paper, electronic files can be deposited as supplementary material
High Visibility Covered in the Science Citation Index Expanded (SCIE - Web of Science) from Vol. 4, and in Scopus. Citations available in PubMed; full-text archived in PubMed Central Aims and Scope Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new thera- peutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products.
The scope of Biomedicines includes: Pathogenesis and mechanisms of diseases Translational medical research Biomaterial in biomedical research Novel targets in various therapeutic areas: cardiovascular, vascular, hematology, oncology, neurology, orthopedics, dermatology, ophthalmology Biomarker discovery and early diagnosis research Drug discovery and drug development, biomedicine, and pharmacotherapy Biopharmaceutical biomedicine: biologics, and biosimilars Nanobiotechnological advances in biomedicine: nanomedicine, nanoscaffold implants (synthetic vascular graft), biosensors, bioimaging, gene therapy, Editorial Office Biomedicines Editorial Office vaccine, cell therapy, and tissue engineering. [email protected] MDPI, St. Alban-Anlage 66 4052 Basel, Switzerland Tel: +41 61 683 77 34 Fax: +41 61 302 89 18 www.mdpi.com mdpi.com/journal/biomedicines MDPI is a member of
Follow Us
facebook.com/MDPIOpenAccessPublishing
twitter.com/MDPIOpenAccess
linkedin.com/company/mdpi
weibo.com/mdpicn
Wechat: MDPI-China
blog.mdpi.com
www.mdpi.com mdpi.com/journal/biomedicines
See www.mdpi.com for a full list of offices and contact information. MDPI is a company registered in Basel, Switzerland, No. CH-270.3.014.334-3, whose registered office is at St. Alban-Anlage 66, CH-4052 Basel, Switzerland.
Basel, July 2021